Pasar al contenido principal

MEDICINA DE PRECISIÓN EN NEUROPATÍAS AUTOINMUNES

PI22/00387

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology

  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Vidal-Fernández, Núria|||0009-0008-3749-6448
  • Tejada-Illa, Clara|||0009-0008-2856-7179
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Llansó, Laura|||0000-0003-4950-7657
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Shock, Anthony|||0000-0002-9971-8789
  • Christodoulou, Louis
  • Dizier, Benjamin
  • Freeth, Jim
  • Soden, Jo
  • Dawson, Sarah
  • Querol, Luis|||0000-0002-4289-8264
Background and Objectives Autoantibody discovery in complex autoimmune diseases is challenging. Diverse successful antigen identification strategies are available, but, so far, have often been unsuccessful, especially in the discovery of protein antigens in which conformational and post-translational modification are critical. Our study assesses the utility of a human membrane and secreted protein microarray technology to detect autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods A cell microarray consisting of human embryonic kidney-293 cells expressing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A nationwide Guillain-Barré syndrome epidemiological study in Spain during the COVID-19 years

  • Blanco-Ruiz, M.
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Tejada-Illa, Clara|||0009-0008-2856-7179
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Llansó, Laura|||0000-0003-4950-7657
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Amaya Pascasio, L.
  • Querol, Luis|||0000-0002-4289-8264
Background and purpose: The purpose was to perform a nationwide epidemiological study of Guillain-Barré syndrome (GBS) in Spain, analysing background incidences and seasonal variation and trying to identify incidence changes during the coronavirus disease 2019 (COVID-19) years. Methods: This was an observational study collecting all GBS diagnoses from the National Epidemiological Surveillance Network collected by the Ministry of Health. Patients discharged with GBS as the main diagnosis and admitted during 2018-2021 were included. Data on the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were obtained from the National Epidemiology Centre. Results: In total, 3147 cases were included, 832 in 2018, 861 in 2019, 670 in 2020 and 784 in 2021. Nationwide hospital incidence was 1.78 in 2018, 1.71 in 2019, 1.41 in 2020 and 1.66 in 2021, with an increased frequency in males, the elderly population and in the winter season. Eleven per cent of GBS patients needed ventilatory support. GBS and SARS-CoV-2 incidences did not correlate with one another (r = -0.29, p = 0.36). GBS incidence decreased during 2020 and during the COVID-19 lockdown period in comparison to the same months of 2018-2019. Conclusions: The incidence of GBS in Spain is similar to that of other countries. Despite prior reports describing a significant increase in COVID-19-associated GBS in Spain, a significant drop of GBS incidence during the SARS-CoV-2 pandemic was detected, probably due to prevention measures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibodies in Autoimmune Neuropathies

  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Querol, Luis|||0000-0002-4289-8264
Autoimmune neuropathies are a heterogeneous group of immune-mediated disorders of the peripheral nerves. Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are the archetypal acute and chronic forms. Over the past few decades, pathogenic antibodies targeting antigens of the peripheral nervous system and driving peripheral nerve damage in selected patients have been described. Moreover, the detection of these antibodies has diagnostic and therapeutic implications that have prompted a modification of the GBS and CIDP diagnostic algorithms. GBS diagnosis is based in clinical criteria, and systematic testing of anti-ganglioside antibodies is not required. Nonetheless, a positive anti-ganglioside antibody test may support the clinical suspicion when diagnosis of GBS (GM1 IgG), Miller Fisher (GQ1b IgG), or acute sensory-ataxic (GD1b IgG) syndromes is uncertain. Anti-myelin-associated glycoprotein (MAG) IgM and anti-disialosyl IgM antibodies are key in the diagnosis of anti-MAG neuropathy and chronic ataxic neuropathy, ophthalmoplegia, M-protein, cold agglutinins, and disialosyl antibodies spectrum neuropathies, respectively, and help differentiating these conditions from CIDP. Recently, the field has been boosted by the discovery of pathogenic antibodies targeting proteins of the node of Ranvier contactin-1, contactin-associated protein 1, and nodal and paranodal isoforms of neurofascin (NF140, NF186, or NF155). These antibodies define subgroups of patients with specific clinical (most importantly poor or partial response to conventional therapies and excellent response to anti-CD20 therapy) and pathologic (node of Ranvier disruption in the absence of inflammation) features that led to the definition of the "autoimmune nodopathy" diagnostic category and to the incorporation of nodal/paranodal antibodies to clinical routine testing. The purpose of this review was to provide a practical vision for the general neurologist of the use of antibodies in the clinical assessment of autoimmune neuropathies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Digital biomechanical assessment of gait in patients with peripheral neuropathies

  • Tejada-Illa, Clara|||0009-0008-2856-7179
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vidal-Fernández, Núria|||0009-0008-3749-6448
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Llansó, Laura|||0000-0003-4950-7657
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Querol, Luis|||0000-0002-4289-8264
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Claramunt-Molet, Mireia
  • Pi-Cervera, Ariadna
  • Heras-Delgado, Ainhoa
  • Gascón-Fontal, Jesus
  • Idelsohn Zielonka, Sebastian
  • Rico, Mari
Background: The clinical status and treatment response of patients with peripheral neuropathies (PNs) rely on subjective and inaccurate clinical scales. Wearable sensors have been evaluated successfully in other neurological conditions to study gait and balance. Our aim was to explore the ability of biomechanical analysis using wearable technology to monitor disease activity in PN. Methods: We conducted a single-center, longitudinal study to analyze gait parameters in PN patients and healthy controls using wearable biomechanical sensors. We used a novel technology that registers and integrates data from multiple wearable inertial sensors placed at different locations and plantar insoles. This system allows measuring kinematics, spatio-temporal parameters and plantar pressure. Patients wore the wearable system while performing the 2-min walking test (2MWT). Results: We included 37 chronic inflammatory demyelinating polyneuropathy (CIDP) patients, 3 chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein (CANOMAD) patients, 21 monoclonal gammopathy patients of undetermined significance associated with IgM (IgM-MGUS) patients, 7 patients with autoimmune nodopathies, 11 patients with hereditary neuropathies, and 50 healthy controls. First, we analyzed the sensor's ability to detect changes in ataxia and steppage gait severity and found significant differences in spatiotemporal and angular variables of the gait cycle. Second, we found correlations between biomechanical features and clinical scales and with the specific gait phenotype they associated with. Finally, we demonstrated that this technology is able to capture clinically significant changes in gait features over time. Conclusions: Our study provides proof-of-concept that wearable technology effectively detects and grades gait impairment, captures clinically relevant changes, and could enhance gait assessment in routine care and clinical research for patients with PN.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing

  • Lleixà, Cinta|||0000-0002-9971-0584
  • Fehmi, Janev|||0000-0002-2329-5708
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Waters, Patrick
  • Willison, Hugh John|||0000-0002-5997-1683
  • Querol, Luis|||0000-0002-4289-8264
  • Huizinga, Ruth
  • Doppler, Kathrin
  • Rinaldi, Simon|||0000-0003-2039-3457
  • Titulaer, Maarten
  • Rohrbacher, Sophia
  • Mgbachi, Victor
  • Halstead, Susan
  • Zhu, Louisa
  • Appeltshauser, Luise
  • Franken, Suzanne
  • Paunovic, Manuela
  • Sommer, Claudia
Background and Aims: Reliable detection of antibodies against nodal targets is vital for the diagnosis of autoimmune nodopathies. The performance characteristics of recently developed in-house assays are unknown. We compared testing at four centres. Methods: Each submitted 29-40 serum samples to a coordinating centre from one of three groups: (1) autoimmune nodopathy patients, with positive nodal/paranodal antibodies; (2) seronegative patients with other inflammatory neuropathies, and (3) healthy individuals or those with other neurological diseases. The coordinating centre recoded all samples and returned 160 identical aliquots to each testing centre for blinded testing. Once data from all centres had been received by the coordinating centre, unblinded results were returned for analysis. Sensitivity was defined by the proportion of group 1 samples returned as positive. Accuracy was defined as 0.075(sensitivity) + 0.925(specificity). Results: Centres performed various combinations of ELISA, cell-based (CBAs) and teased-nerve fibre assays. All labs produced highly accurate results (96%-100%) and concordance for the overall result across at least 3 or all 4 test centres was observed for 98% and 89% of the samples respectively. However, 10/30 individual assays (6/14 CBAs and 4/16 ELISAs) were less than 90% sensitive. Only 3 assays had more than 1 false positive result (2 ELISAs and 1 CBA). Combining different assay modalities to produce an overall result did not improve accuracy. Inter-laboratory consistency in the determination of antibody subclasses was poor. Interpretation: Although most samples were correctly categorised in all 4 centres, the use of a specific test modality or multiple tests did not guarantee accuracy. Early and repeated interlaboratory testing with sharing of samples is important to understand test performance and reproducibility, identify areas for improvement and maintain consistency. To aid this, we provide detailed methods for the best performing tests. Further standardisation of antibody subclass determination is required.